Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study

Levofloxacin as primary prophylaxis in patients with AML treated with VEN-AZA seems to decrease the rate of documented infections even if the incidence of FN was not significantly decreased. This prophylaxis shaped a different clinical and microbiological landscape without significant increase of antibiotic resistance.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2025-02-24
DOI
https://doi.org/10.1093/ofid/ofaf105
Citations
1
Primary Topic
Neutropenia and Cancer Infections
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study

Nathan Mottal, Jennifer Guiraud, Éric Delabesse, Christian Récher et al.
1 citations
Open Forum Infectious Diseases
Neutropenia and Cancer Infections
1.05
article

Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study

Nathan Mottal, Jennifer Guiraud, Éric Delabesse, Christian Récher, Martin Gauthier, Anne‐Charlotte de Grande, Harmony Leroy, Diane Lara, Pierre‐Yves Dumas, Xavier Brousse, Audrey Bidet, Emilie Bérard, Sarah Bertoli, Thibaut Leguay, Pauline Floch, K. Delavigne, Leila Ghenim, Léopoldine Lapierre, Arnaud Pigneux, Audrey Sarry, Suzanne Tavitian, Nicolas Rasandisona, Clémentine Béranger, Anne Banos
article en
1 citations

Abstract

Levofloxacin as primary prophylaxis in patients with AML treated with VEN-AZA seems to decrease the rate of documented infections even if the incidence of FN was not significantly decreased. This prophylaxis shaped a different clinical and microbiological landscape without significant increase of antibiotic resistance.

Open Forum Infectious DiseasesVol. 12(3)
Université Toulouse III - Paul Sabatier (FR), Inserm (FR), Université Fédérale de Toulouse Midi-Pyrénées (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Toulouse (FR), Rode Kruis Ziekenhuis (NL), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre Hospitalier de la Côte Basque (FR), Groupe Cahors (France) (FR)
Good health and well-being
Openalex Percentile: Top 25%
Neutropenia and Cancer Infections
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.